Global Biotech is surging as policy fears fade and innovation takes centre stage. Here’s what’s driving the comeback into ...

Akeso has a validated process in place for developing antibodies but does require US exposure to meet its lofty valuation.

The firm will initially seek approval in patients who've had prior ALK inhibitors but has ambitions to eventually make neladalkib a first-line option.

A new analysis from Jefferies shows that drugs receiving breakthrough designations sail through the regulatory process more ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

AstraZeneca receives FDA approval for Koselugo to treat adults with NF1 and inoperable plexiform neurofibromas, backed by ...

Vaccinations have been completed and Valneva expects VALOR trial outcomes to be announced in the first half of 2026, followed by regulatory submissions as planned. Pfizer aims to submit a Biologics ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

Agios Pharmaceuticals, Inc. drops after mixed Phase 3 mitapivat results in Sickle Cell Disease. Click here to find out why ...

The company declined to comment on Gottlieb’s appointment, which comes as it works to improve its relationship with federal ...

In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle | ...

UnitedHealth Group said on Tuesday it had named former U.S. Food and Drug Administration commissioner Scott Gottlieb to its ...